Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 560 participants.
Also called NCT07129421
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 560 participants
- Registry
-
NCT07129421
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07129421. Randomized; single masking; primary purpose prevention. Start 2025-10-21 (anticipated); primary completion 2027-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Safety and Effectiveness of the EMBLOK EPS Compared With No Cerebral Embolic Protection During TAVR
- Acronym
- EMBLOK II
- Condition
- AORTIC VALVE DISEASES
- Condition
- Aortic Valve Stenosis and/or Insufficiency
- Condition
- Aortic Valve Regurgitation
- Condition
- Aortic Valve Replacement
- Intervention (Device)
- EMBLOK™ Embolic Protection System ("EMBLOK EPS")
- Lead sponsor
- Emblok, Inc.
- Collaborator
- Yale Cardiovascular Research Group
Record details
- Record id
cardio:ct-nct07129421- Content hash
b4f9a2cd202665bf9cf231eb4c481fe7d5c419a307d902d3e3b6b8518e24b93d